Retatrutide: A Research Overview of the Triple Agonist
Retatrutide (development code LY3437943) is a synthetic 39-residue peptide engineered to activate three related G protein-coupled receptors at once: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). Because it engages all three, it has become a reference compound in laboratory work on incretin biology and energy metabolism. This overview summarises its structure, its receptor pharmacology, the preclinical findings reported in the primary literature, and the practical considerations for handling the material in a research setting.
Background: why a triple agonist?
The incretin hormones GLP-1 and GIP are secreted by the gut in response to nutrients and signal through class B GPCRs, raising intracellular cAMP in target cells. Glucagon, secreted by pancreatic alpha cells, signals through a closely related receptor and has long been studied for its roles in hepatic glucose output, lipid handling and energy expenditure. Native versions of all three hormones are short-lived in circulation, which limits their usefulness as research tools for sustained-exposure experiments.
Medicinal chemistry programmes therefore turned to analogues that retain receptor activity while resisting enzymatic degradation and clearance. Single agonists of GLP-1R, and later dual agonists of GLP-1R and GIPR such as tirzepatide, established that pharmacological engagement of multiple incretin-family receptors is experimentally tractable. Retatrutide extends this logic by adding glucagon receptor activity to the GIPR and GLP-1R profile, allowing investigators to study how three signalling axes interact within one molecule. A side-by-side discussion of the two compounds is available in the PureX Labs article Retatrutide vs Tirzepatide: Receptor Targets Compared.
Molecular structure and chemical identity
Retatrutide is registered under CAS number 2381089-83-2, with a molecular formula of C221H342N46O68 and a formula weight of approximately 4,731 Da, as listed by commercial reference-standard suppliers such as Cayman Chemical. The sequence is based on the incretin peptide scaffold and contains non-proteinogenic residues, notably alpha-aminoisobutyric acid (Aib) and alpha-methyl-leucine, which are introduced to protect the backbone from peptidase cleavage. The C-terminus is amidated.
Lipidation and half-life extension
A lysine side chain within the sequence carries a linker-attached C20 fatty diacid moiety (an AEEA and gamma-glutamic acid spacer joined to the diacid). This type of acylation promotes reversible binding to serum albumin, which slows renal clearance and extends the molecule's circulating lifetime. In the original discovery report, the pharmacokinetic profile was described as compatible with once-weekly dosing intervals in the clinical setting (Coskun et al., Cell Metabolism, 2022). From a laboratory standpoint, the practical consequence of this design is a long-acting compound, which is relevant when planning exposure windows in in vivo animal experiments.
Receptor pharmacology
The defining feature of retatrutide is its unequal engagement of the three receptors. In the Coskun et al. (2022) characterisation, the peptide displayed balanced activity at GCGR and GLP-1R in in vitro assays and notably stronger activity at GIPR. Supplier reference data reporting cAMP accumulation in HEK293 cells expressing each human receptor give EC50 values of roughly 0.064 nM for GIPR, 0.775 nM for GLP-1R and 5.79 nM for GCGR. Read together, these figures indicate that GIPR is engaged at the lowest concentrations, followed by GLP-1R, with glucagon receptor activation requiring somewhat higher concentrations. Values of this type are assay-dependent and should be treated as indicative rather than universal.
Downstream signalling
All three receptors couple predominantly to Gs and increase intracellular cAMP, but they are expressed in different tissue distributions and are therefore thought to contribute distinct effects in intact systems. In the framework proposed by the discovery authors, GLP-1R and GIPR activity is associated with changes in feeding behaviour and glucose-dependent insulin secretion, while GCGR activity is associated with increased energy expenditure. Whether these attributions hold across species and experimental conditions remains an active question in the literature, and they are best understood as hypotheses supported by specific data sets rather than settled mechanisms.
Preclinical findings
The key preclinical data come from the Coskun et al. (2022) paper, which reported experiments in diet-induced obese mice. In that work, the triple agonist reduced body weight and improved measures of glycaemic control. A central observation was that the weight reduction exceeded what would be expected from reduced food intake alone: the authors attributed the additional effect to GCGR-mediated increases in energy expenditure layered on top of the intake-lowering effects of GIPR and GLP-1R activation. The study also included metabolomic analysis, which the authors used to explore metabolic changes associated with glucagon receptor engagement.
These observations are limited to the model systems described. Rodent metabolism differs from that of other species in important respects, including basal metabolic rate, brown adipose tissue contribution and receptor expression patterns, so cross-species extrapolation requires caution. For investigators, the paper's main value is as a documented example of how a triple agonist behaves in a defined obese-mouse paradigm, providing a benchmark against which dual agonists, single agonists and other analogues can be compared.
Comparison with related research compounds
Relative to a GLP-1R-selective analogue such as semaglutide, retatrutide adds two further receptor targets. Relative to a GIPR/GLP-1R dual agonist, it adds glucagon receptor activity. This graded series, single, dual and triple agonism, has allowed laboratories to ask how each additional receptor changes outcome measures such as food intake, energy expenditure, hepatic lipid content and glucose tolerance in animal models. Careful experimental design, including receptor-selective antagonists and knockout or knock-in models, is generally required to separate the contribution of each pathway.
It is worth noting that human clinical investigations of this compound have been conducted and published separately by the originating sponsor. Those studies fall outside the scope of this laboratory-focused overview, and nothing here should be read as describing a use, benefit or outcome in people. The material supplied for research is intended only for in vitro and non-human experimental work.
Handling and storage considerations
As with most lyophilised peptides, retatrutide is typically supplied as a solid and stored at −20°C or below, protected from light and moisture. Supplier data indicate only slight solubility in neutral phosphate buffers, in the range of 0.1–1 mg/mL, so solvent selection and pH should be confirmed on a small aliquot before preparing working stocks. Repeated freeze-thaw cycles should be avoided by aliquoting reconstituted material, and containers should be allowed to reach room temperature before opening to limit condensation. General guidance on storage and reconstitution technique applies here as it does for other lyophilised peptides.
Verifying identity and purity
Because the molecule is large, lipidated and contains non-standard residues, identity confirmation should combine HPLC for purity with mass spectrometry for molecular weight; an observed mass near 4,731 Da is the expected match. Batch documentation for PureX Labs materials, including analytical reports, can be reviewed on the Lab Results page, and research-grade retatrutide is listed in the catalogue.
Experimental design notes
When retatrutide is used as a reference agonist, several design variables deserve explicit documentation. Receptor-expressing cell lines should be characterised for expression level, since apparent potency in cAMP assays depends on receptor reserve. Vehicle composition, including any carrier protein or detergent used to limit adsorption of a lipidated peptide to plasticware, should be reported alongside concentrations. In animal work, pair-fed control groups are frequently included so that effects attributable to reduced intake can be separated from effects on energy expenditure, and indirect calorimetry is the standard method for measuring the latter. Reporting these details makes results easier to compare across laboratories and supports reproducibility of the reported pharmacology.
Open questions in the research literature
Several questions remain under investigation: the relative importance of each receptor at different exposure levels, the extent to which glucagon receptor activation contributes in tissues beyond the liver, how receptor desensitisation and internalisation differ among the three targets, and how species differences influence translation of rodent findings. Biased agonism, in which a ligand preferentially activates one intracellular pathway over another at the same receptor, is also an area of interest for multi-agonist design. Continued publication of primary pharmacology will refine understanding of how this class of molecules behaves in controlled systems.
Summary
Retatrutide is a lipidated, protease-resistant 39-residue peptide that activates GIPR, GLP-1R and GCGR, with the highest in vitro potency at GIPR. Its primary preclinical characterisation, published in Cell Metabolism in 2022, reported body-weight and glycaemic changes in obese mice and linked glucagon receptor activity to increased energy expenditure. For laboratories, it serves as a well-defined tool for comparing single, dual and triple incretin-family receptor agonism, provided that identity, purity and storage conditions are verified and that findings are interpreted within the limits of the model used.
Research use only. Not a medicine, supplement or therapeutic good. Not for human or veterinary consumption.